Health Care [ 12/12 ] | Biotechnology [ 66/74 ]
NASDAQ | Common Stock
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States.
The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders.
The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases.
Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -1.03 Decreased by -39.19% | -1.11 Increased by +7.21% |
| May 9, 24 | -1.09 Increased by +9.17% | -1.00 Decreased by -9.00% |
| Mar 21, 24 | -0.90 Increased by +26.23% | -0.78 Decreased by -15.38% |
| Nov 9, 23 | -0.58 Decreased by -625.00% | -0.80 Increased by +27.50% |
| Aug 11, 23 | -0.74 Increased by +53.75% | -0.86 Increased by +13.95% |
| May 15, 23 | -1.20 Increased by +65.71% | -0.68 Decreased by -76.47% |
| Mar 31, 23 | -1.22 Increased by +70.24% | -0.76 Decreased by -60.53% |
| Nov 10, 22 | -0.08 Increased by +98.14% | -0.09 Increased by +11.11% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -26.60 M Decreased by -88.35% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -26.35 M Decreased by -65.25% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -26.95 M Decreased by -18.30% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -23.58 M Decreased by -15.44% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -14.12 M Decreased by -408.72% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -15.95 M Decreased by -131.18% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -22.78 M Decreased by -49.69% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -20.43 M Decreased by -14.60% | Decreased by N/A% Decreased by N/A% |